Tempest Therapeutics
TPST
17 hedge funds and large institutions have $6.02M invested in Tempest Therapeutics in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 4 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
6% less funds holding
Funds holding: 18 → 17 (-1)
6% less capital invested
Capital invested by funds: $6.42M → $6.02M (-$401K)
12.46% less ownership
Funds ownership: 25.65% → 13.19% (-12%)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $20K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$243K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
+$163K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$54.6K |
| 4 |
Belvedere Trading
Chicago,
Illinois
|
+$46.2K |
| 5 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$1.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.88M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$945K |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$10.4K |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
-$1.59K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.55K |
TPST Hedge Fund Activity: Q3 2025 in Review
17 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2025, worth a combined $6.02M — down 6.2% from $6.42M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TPST and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $243K. The largest seller was Sabby Management, exiting entirely with an estimated $1.88M sold.
- 17 institutional investors held Tempest Therapeutics (TPST) as of Q3 2025, down from 18 in Q2 2025.
- Funds reported $6.02M of Tempest Therapeutics stock for Q3 2025, down 6.2% quarter-over-quarter.
- 3 funds opened new Tempest Therapeutics positions in Q3 2025 and 4 closed out, a net change of -1 holder.
- The largest Tempest Therapeutics buyer in Q3 2025 was Vanguard Group, an estimated $243K added.
- The largest Tempest Therapeutics seller in Q3 2025 was Sabby Management, an estimated $1.88M sold.
Based on aggregated 13F filings for Q3 2025.